SAN DIEGO and SEATTLE, Oct. 4 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today the successful completion of a Phase 1 clinical study for VTX-2337, its novel TLR8 agonist for oncology at the International Society for Biological Therapy of Cancer (ISBTC). In a poster entitled "First-in-Man Phase I Clinical Trial of VTX-2337A Selective Toll-Like Receptor 8 (TLR8) AgonistIn Oncology Patients," VTX-2337 was proven to be safe and well tolerated with a predictable pharmacokinetic profile in 33 patients. In addition, VTX-2337 showed dose-dependent pharmacologic activity.
Additionally, George Coukos,
M.D., Ph.D., Associate Chief of the Division of Gynecologic Oncology
and Director of the Ovarian Cancer Research Center at the University of Pennsylvania
Abramson Cancer Center presented preclinical data combining VTX-2337
with Doxil chemotherapy in a poster also at ISBTC entitled "TLR8 Agonist
and Doxil chemotherapy potently activate human antitumor immune
response in a human immune system mouse model." Read More